Camptosar Patient Genotype Testing For Neutropenia Risk Marker Advised

Patient genotype is a predictive factor for neutropenic adverse events in patients receiving Pfizer's oncologic Camptosar, FDA's Clinical Pharmacology Subcommittee of the Pharmaceutical Science Advisory Committee agreed Nov. 3